Summary
A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clinical brochure for AT-125(NSC-163501,(L-(5, 5S)-amino-3-chloro-4, 5-dihydro-5-isoxazole acetic acid)) April 1979
Houchens DP, Ovejera AA, Sheridan MA, Johnson RK, Bogden AE, Neil GL: Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63:473–475, 1979
McGovern JP, Stewart JC, Elfring GL, Smith RB, Scares N, Wood JH, Poplack DG, Von Hoff DD: Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing Rhesus monkeys. Cancer Treat Rep 65: 1333–1341, 1982
McGovern P, Pratt EA: Pharmacokinetics of acivicin (AT-125) in the phase I clinical trials. (Abstract). Proc Am Soc Clin Oncol 22:356, 1981
Jayaram NH, Cooney DA, Ryan JA, Neil GL, Dion RL, Bono VH: L-[5,5S]-amino-3 chloro-4,5-dihydro-5 isoxazole acetic acid (NSC 163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother Rep 59:481–491, 1975
Physiological Reviews (2) 54:418–540, 1974
Waser PG: The pharmacology of amanita muscaria. In: Efron DH, Holmstedt B, Kline NS (eds): Ethnopharmacologic Search for Psychoactive Drugs. U.S. Public Health Services Publication No. 1645, Washington D.C., pp 419–439, 1967
Catane R, Von Hoff DD, Glaubiger DL, Muggia FM: Azaserine, DON, and Azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer Treat Rep 63:1033–1038, 1979
Kovach JS, Eagan RT, Powis G, Rubin J, Creagan EG, Moertel CG: Phase I and pharmacokinetics of DON. Cancer Treat Rep 65:1031–1036, 1981
Ellison RR, Karnofsky DA, Sternberg SS, Murphy ML, Burchenal JH: Clinical trials of O-Diazoacetyl-L-Serine (Azaserine) in neoplastic disease. Cancer 7:801–814, 1954
Woolley PV, Schein PS: Clinical pharmacology and phase I trial design. In: Methods in Cancer Research, Vol. XVII, Academic Press, 1979, pp 177–198
Murphy WK, Burgess MA, Valdivieso M, Bodey GP: Phase I evaluation of acivicin (AT-125). (Abstract) Proc Am Soc Clin Oncol 1:23, 1982
Adolphson C, Bedikian AY, Stroehlein JR, Karlin DA, Bodey GP, Hickey RC: Phase II evaluation of acivicin (AT-125, NSC 163501) in patients with advanced colorectal cancer. (Abstract) Proc Am Soc Clin Oncol 1:96, 1982
Ohnuma T, Sridhar K, Goldsmith M, Bruckner H, Chahinian AP, Holland JF: A phase I study of acivicin (AT-125). (Abstract) Proc Am Soc Clin Oncol 22:382, 1981